About NeuroEM
NeuroEM Therapeutics® is a Tampa-based medical device company committed to developing, clinically testing, and marketing Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF) to effectively prevent and treat cognitive decline caused by aging or Alzheimer’s and other neurodegenerative diseases.
Clinical results indicate that our non-invasive bioengineered technology has the potential to stop and reverse the progressive memory impairment of Alzheimer’s disease.
First-in-class device designed to fight Alzheimer’s
NeuroEM Therapeutics’ “first-in-class” MemorEM™ device was designed to be comfortably worn on the head to administer TEMT-RF during daily in-home treatment.
Our pioneering TEMT-RF technology has shown extraordinary promise against Alzheimer’s in all completed preclinical and clinical studies.
The electromagnetic waves emanating from multiple emitters in the wearable head cap disaggregate toxic protein ‘oligomers’ within neurons throughout the brain. Since these oligomers are increasingly believed to be the root cause of Alzheimer’s disease, we believe the MemorEM head device will directly attack the Alzheimer’s disease process.
TEMT-RF has two additional mechanisms of action that attack Alzheimer’s and other causes of cognitive decline – TEMT-RF re-balances the immune system in both brain and blood and TEMT-RF increases the energy production of brain cells.
NeuroEM’s MemorEM device will be available through neurologists and other health professionals who diagnose memory disorders once we complete our pivotal trials and receive FDA approval.
Leadership Team
-
Chuck Papageorgiou
Chief Executive Officer
-
Tracy Ingram
Chief Operating
& Information Officer -
Amanda Patanow
Chief Marketing
& Product Officer -
Marilyn Thompson
Chief Financial Officer
-
Edward Goodwin, Ph.D.
Chief Scientist
-
Chuanhai Cao, MPH, Ph.D.
Head of USF Research Team
-
Rob Baranowski
Sr. Engineer
Product Development -
Patty Meagher
Community Advocate
Directors & Advisors
Jonathan Gordon
Chairman of the Board
Jon is a co-founder and managing partner of Stage One Ventures an early-stage venture capital firm, founded in 2006. He has been a successful executive, entrepreneur, and investor for over 30 years. He has been at the forefront of many historic market and technological changes in the high-tech global economy. Jon led Investments in e-Centives (sold to Catalina Marketing), AdelaVoice, Marxent Labs, Maple Farm Media, Carvoyant, Par Elastic, Instream, Veloxum, XPeerient, Delfigo Security, Wing Power, Phantom Alert, OnePin, Cuesol (sold to MobileLime), go2 (merged with 80108), SiteWit and Auspice (sold to Arris), SiteWit, and KiteDesk.
Jon is an accomplished executive, entrepreneur, and investor with over 40 years of experience in building technology companies from early and mid-stage to successful exits. His expertise spans enterprise software, system software, semiconductors, and instrumentation industries. Jon is adept at enhancing shareholder value through business development, establishing sales and market channels, ensuring timely product development, and managing operations cost-effectively to achieve profitability. Moreover, he has specialized knowledge in intellectual property monetization and maintains a wide network of high-level global relationships.
Mitch Lairmore
Director and Proxy for Dr. Arendash
Mitch Lairmore has a strong background in business development, strategic planning, and market research, with extensive experience in the commercialization of technology. He has led product development teams and supported small companies in obtaining SBIR grants from NASA, the US Air Force, and the NSF. As a staff consultant, Mitch provided commercialization assistance to projects funded by the US Navy, the Department of Energy, the National Science Foundation, the Department of Transportation, and the Department of Homeland Security.
Before these roles, he was a subcontractor to a prime contractor for major agencies such as the National Institute of Health, the Department of Energy, and the Environmental Protection Agency. At Eastman Kodak, Mitch served as a business development director, where he was responsible for strategic planning for new products and intellectual property licensing. He co-founded a venture within Kodak’s New Opportunity Development initiative and managed a significant data storage product development effort, securing partnerships and funding.
Mitch was also a board member for a Kodak Ventures Group company, guiding it to profitability. He holds a Certified Global Business Professional certification through the National Association of Small Business International Trade Educators and has assisted small businesses in expanding their international reach. Mitch earned an MBA from the William E. Simon Graduate School of Business Administration at the University of Rochester and a B.S. in Industrial Engineering from the University of Iowa.
Gary Arendash, Ph.D.
Founder & Scientist Emeritus
Dr. Arendash served as a Full Professor and Research Professor at the University of South Florida for 30 years. During his final six years there, he directed the Florida Alzheimer’s Disease Research Center’s Animal Core and one of its three principal research initiatives. Specializing in the development of Alzheimer's disease therapeutics, Dr. Arendash has published over 120 peer-reviewed articles in first-tier journals, such as Science, Nature, and the Journal of Alzheimer’s Disease, where he served as Senior Editor until 2017. During his tenure at USF, he secured $5 million in research funding from external agencies, including the National Institutes of Health (NIH) and the Alzheimer’s Disease and Related Disorders Association (ADRDA). Dr. Arendash was among the pioneers to demonstrate that Alzheimer's Disease begins in the brain decades before its clinical diagnosis. His landmark study in 2010 provided initial evidence that electromagnetic treatment induces cognitive benefits in Alzheimer's mice through multiple disease-modifying mechanisms. He further advanced this promising pre-clinical research by conducting three clinical studies from 2019 to 2023, which demonstrated the safety and efficacy of the technology he developed against Alzheimer’s. Dr. Arendash received his Ph.D. in Neuroscience/Physiology from the University of California, San Francisco (UCSF) and completed his post-doctoral research at UCLA’s Brain Research Institute before joining the University of South Florida faculty.
Kim H. Manwaring, MD
Medical Advisor
Dr. Manwaring is a board certified pediatric neurosurgeon and inventor of six commercialized devices used throughout the world in various specialties. These include conception of the most widely used intracranial pressure sensor (Codman Microsensor), first approved FDA cranial orthosis (DOCband), Stryker Colorado Microneedle, and the FMwand ferromagnetic energy modality. He holds 25 patents for a variety of surgical tools. He is also a recipient of various awards, including the Physician Achievement Award from the Children's Miracle Network, and is listed in America's Best Doctors. He has lectured in many countries on surgical technique and innovations.
Dr. Manwaring practices pediatric neurosurgery part time at Arnold Palmer Children's Hospital in Orlando. He has also functioned as an adjunct professor of Neuroscience at Brigham Young University. He is CMO of Mu Implant Technologies, LLC. He principally undertakes bench research and prototype design of instruments and transducers, functioning as the Principle Inventor of the FMwand system of Domain Surgical Inc.
Lloyd Marks, MD, MBA, FACC
Medical Advisor
Dr. Marks is a pediatric cardiologist, electrical engineer, MBA, and inventor. Renowned for his innovation in the medical field, he boasts over 20 medical device patents, the majority of which have been successfully licensed to various industry leaders. As an entrepreneur, Dr. Marks has founded three startup companies, including one currently commercializing his medical invention. He is also a committed mentor, guiding student startups, and serves as an advisor to academic institutions, inventors, corporations, and investors. He regularly supports investors’ conducting due diligence and patent attorneys regarding the assessment, protection, and commercialization of medical technology. Dr. Marks completed his Bachelor of Science in Electrical and Electronics Engineering at the Massachusetts Institute of Technology, his MD at the University of Michigan Medical School, and an MBA for Physician Executives at the University of Tennessee, Knoxville.
William Scott Burgin, MD
Medical Advisor
Dr. Burgin, a professor of neurology and stroke division chief at the University of South Florida, brings a wealth of expertise to the field of neurology, including clinical care, research, administration, and teaching. His extensive background includes a deep focus on stroke-related artificial intelligence (AI), biomarkers, and intellectual property (IP) development. Throughout his distinguished career, Dr. Burgin has made significant contributions to the medical community, evidenced by his authorship of over 100 peer-reviewed articles and active contributions to more than 75 clinical research projects.
Dr. Burgin is passionate about leveraging innovative technologies to enhance patient outcomes. In addition to his role on the NeuroEM medical advisory board, he currently serves as the Chief Medical Advisor for a biotechnology company in Tampa. He has also co-founded two pioneering companies in the Tampa Bay region. One focuses on novel neuroprotectant approaches, exploring new methods to safeguard and restore neural function. The other harnesses the power of AI to assist stroke patients with communication disorders, fostering improved communication and increased independence.
By combining his academic prowess with his entrepreneurial spirit, Dr. Burgin continues to make a lasting impact on the neurological community and beyond.
Stephen Hull
Reimbursement Advisor
Stephen Hull is a Reimbursement Advisor for NeuroEM, specializing in creating integrated market strategies for innovative technologies throughout their entire product lifecycle. Prior to his role as Sr. Vice President of Market Access, Avania, Stephen founded Hull Associates, a global market access and reimbursement strategy firm working in all major therapeutic areas across 22 markets worldwide. A staunch advocate for life-saving innovations, Stephen has dedicated his career to enhancing patient access to life-saving innovations. He has chaired committees for the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
Stephen holds an advanced degree in health policy from the Johns Hopkins Bloomberg School of Public Health and a bachelor’s degree in international relations and French from Colgate University. Based near Boston, Massachusetts, he is a sought-after speaker for US and international forums on payment systems and the reimbursement of pharmaceuticals, medical devices, and in vitro diagnostics.
Partners and Collaborators
-
Left Coast Engineering
Rob Baranowski,
Senior Engineering Project Lead -
RF Exposure Lab
Jay Moulton,
Vice-President -
Ocotillo Electromagnetics
David Wittwer, Ph.D.
Richard Ziolkowski, Ph.D. -
Remarkable Technologies
Eric Knight,
President
-
USF Health/Byrd Alzheimer’s Institute
Amanda Smith, M.D.
-
Axiom Clinical Research of Florida
Susan Steen, M.D.
Haitham Abulaban, MBBS, CCRC -
Invicro/Konica Minolta
Gary Wisniewski, Ph.D.
Lino Becerra, M.D. -
MegaNano Biotech Inc.
Chuanhai Cao, Ph.D.
-
University of South Florida
Dr. Chuanhai Cao, Ph.D.
Ziaopeng Li, Ph.D.
Jing Wang, Ph.D.